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Introduction
TMC278 had a high virologic response rate, non-inferior
to EFV, in two Phase III double-blind trials ECHO
(TMC278-C209, NCT00540449) and THRIVE (TMC278-
C215, NCT00543725) in treatment-naïve HIV-infected
adult patients. As the use of NNRTIs, particularly nevira-
pine, has been associated with hepatic-related adverse
events (AEs), especially in HIV/hepatitis B (HBV) and/or
hepatitis C (HCV) co-infected patients, a subgroup analy-
sis of these events was performed on the pooled Week 48
Phase III data.
Methods
Patients (N=1368) with alanine aminotransferase (ALT)/
aspartate aminotransferase (AST) ≤ 5x upper limit of
normal received TMC278 25mg qd or EFV 600mg qd,
plus TDF/FTC (ECHO) or TDF/FTC, AZT/3TC or
ABC/3TC (THRIVE). HIV/HBV and/or HCV co-infec-
tion status was determined at baseline in 1335 patients
by HBV surface antigen, HCV antibody and RNA
testing.
Results
At baseline, 112/1335 patients (8.4%) had evidence of
HIV/HBV and/or HCV co-infection (randomised to
TMC278, n=49: 7.3%; EFV, n=63: 9.5%). Table 1 sum-
marises the outcomes.
Compared with HIV mono-infected patients, co-
infected patients had more hepatic AEs (clinical and
laboratory) and lower virologic responses, which were
similar across treatment groups. Hepatic AEs rarely led
to treatment discontinuation (TMC278: n=3 vs. EFV:
n=9 patients). There were no fatal hepatic AEs.
Conclusions
Overall, both TMC278 and EFV were well tolerated with
no hepatic safety differences observed. Hepatic AEs were
more common in co-infected than in HIV mono-
infected patients (27% vs. 4%, respectively), but there
were no differences between the two treatment groups.
Virologic responses were similar for TMC278 and EFV
within the co-infected and HIV mono-infected groups,
and lower in co-infected than in HIV mono-infected
patients.
Author details
1Chelsea and Westminster Hospital, London, UK.
2Centro Médico Puerta de
Hierro, Zapopan, Jal, Mexico.
3Saint-Pierre University Hospital, Brussels,
Belgium.
4Centro Médico São Francisco, Curitiba, Brazil.
5University of Miami,
Miami, FL, USA.
6Clinique Medicale du Quartier Latin, Montreal, Canada.
7Beijing PUMC Hospital, Beijing, China.
8University of Pennsylvania,
Philadelphia, PA, USA.
9Tibotec BVBA, Beerse, Belgium.
10Tibotec Inc.,
Titusville, NJ, USA.
Published: 8 November 2010
1Chelsea and Westminster Hospital, London, UK
Full list of author information is available at the end of the article
Nelson et al. Journal of the International AIDS Society 2010, 13(Suppl 4):P210
http://www.jiasociety.org/content/13/S4/P210
© 2010 Nelson et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.doi:10.1186/1758-2652-13-S4-P210
Cite this article as: Nelson et al.: Efficacy and safety of TMC278 in
treatment-naïve, HIV-1-infected patients with HBV/HCV co-infection
enrolled in the phase III ECHO and THRIVE trials. Journal of the
International AIDS Society 2010 13(Suppl 4):P210.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Table 1
HIV/HBV and/or HCV co-infected
patients
HIV mono-infected
patients
TMC278 25mg qd EFV 600mg
qd
TMC278 25mg qd EFV 600mg
qd
Efficacy (Week 48 outcomes)* N=49 N=63 N=621 N=602
% (95% CI) with viral load <50 copies/mL, ITT-
TLOVR
73.5 (60.7-86.3) 79.4 (69.1-
89.6)
85.0 (82.2-87.8) 82.6 (79.5-
85.6)
Mean CD4 count (95% CI) N=48 N=63 N=621 N=602
Baseline, cells/mm
3 230 (198-263) 246 (216-276) 262 (251-273) 274 (262-285)
Change from baseline, NC=F
†, cells/mm
3 +137 (100-175) +192 (147-
238)
+197 (186-209) +173 (161-
185)
Change from baseline, NC=F
†, % +6.6 (5.0-8.3) +7.7 (6.4-9.0) +8.6 (8.1-9.0) +8.4 (7.9-8.8)
Safety
‡,
§
Treatment-emergent hepatic AEs of interest, n (%) N=54 N=66 N=632 N=616
Any hepatic AE 15 (27.8) 17 (25.8) 23 (3.6) 28 (4.5)
Hepatobiliary disorders
Â¶ 3 (5.6) 7 (10.6) 6 (0.9) 9 (1.5)
HBV or HCV reported as an AE 3 (5.6) 5 (7.6) - -
Hepatic laboratory abnormalities reported as an
AE
9 (16.7) 8 (12.1) 19 (3.0) 21 (3.4)
Grade 3 to 4 hepatic laboratory abnormalities, n (%) N=54 N=66 N=631 N=604
ALT increased 9 (16.7) 11 (16.7) 1 (0.2) 12 (2.0)
AST increased 7 (13.0) 5 (7.6) 7 (1.1) 14 (2.3)
Hyperbilirubinaemia 0 0 4 (0.6) 1 (0.2)
ITT-TLOVR = intent-to-treat-time-to-loss of virologic response; CI=confidence interval; *Patients included in efficacy analysis were those with baseline HBV/HCV
assessments; †NC=F = non completer = failure: missing values after discontinuation imputed with change = 0; Last observation carried forward otherwise;
‡Safety analyses performed using all available data, including beyond Week 48; §Patients who seroconverted for HBV/HCV during the study were includedi nt h e
subgroup of HIV/HBV and/or HCV co-infected patients; ¶Selection of preferred terms from System Organ Class as defined by MedDRA. Compared with HIV mono-
infected patients, co-infected patients had more hepatic AEs (clinical and laboratory) and lower virologic responses, which were similar across treatment groups.
Hepatic AEs rarely led to treatment discontinuation (TMC278: n=3 vs. EFV: n=9 patients). There were no fatal hepatic AEs.
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